Similar articles for PMID: 34992153

Year	Number of Results
2002	1
2005	1
2009	1
2010	3
2011	2
2012	4
2013	4
2014	4
2015	4
2016	8
2017	14
2018	7
2019	11
2020	25
2021	29
2022	36
2023	31
2024	31
2025	1

1

Targeted α-Emitter Therapy with ²¹²Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial.

Delpassand ES, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A, Núñez R. Delpassand ES, et al. J Nucl Med. 2022 Sep;63(9):1326-1333. doi: 10.2967/jnumed.121.263230. Epub 2022 Jan 6. J Nucl Med. 2022. PMID: 34992153 Free PMC article.

2

Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog ¹⁷⁷Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.

Zhang J, Wang H, Jacobson O, Cheng Y, Niu G, Li F, Bai C, Zhu Z, Chen X. Zhang J, et al. J Nucl Med. 2018 Nov;59(11):1699-1705. doi: 10.2967/jnumed.118.209841. Epub 2018 Apr 13. J Nucl Med. 2018. PMID: 29653971 Free PMC article. Clinical Trial.

3

Preclinical Investigation of ²¹²Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model.

Stallons TAR, Saidi A, Tworowska I, Delpassand ES, Torgue JJ. Stallons TAR, et al. Mol Cancer Ther. 2019 May;18(5):1012-1021. doi: 10.1158/1535-7163.MCT-18-1103. Epub 2019 Mar 29. Mol Cancer Ther. 2019. PMID: 30926632 Free PMC article.

4

Radiopharmaceuticals used for diagnosis and therapy of NETs.

Papachristou M. Papachristou M. Hell J Nucl Med. 2023 May-Aug;26 Suppl:19-20. Hell J Nucl Med. 2023. PMID: 37658556 Free article.

5

Dose escalation of an Evans blue-modified radiolabeled somatostatin analog ¹⁷⁷Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors.

Liu Q, Cheng Y, Zang J, Sui H, Wang H, Jacobson O, Zhu Z, Chen X. Liu Q, et al. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):947-957. doi: 10.1007/s00259-019-04530-1. Epub 2019 Dec 12. Eur J Nucl Med Mol Imaging. 2020. PMID: 31832728 Free PMC article. Clinical Trial.

6

⁶⁴Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial.

Delpassand ES, Ranganathan D, Wagh N, Shafie A, Gaber A, Abbasi A, Kjaer A, Tworowska I, Núñez R. Delpassand ES, et al. J Nucl Med. 2020 Jun;61(6):890-896. doi: 10.2967/jnumed.119.236091. Epub 2020 Jan 10. J Nucl Med. 2020. PMID: 31924723 Free article. Clinical Trial.

7

Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.

Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, Erion JL, O'Dorisio TM, Kvols LK, Simon J, Wolfangel R, Camp A, Krenning EP, Mojtahedi A. Delpassand ES, et al. Pancreas. 2014 May;43(4):518-25. doi: 10.1097/MPA.0000000000000113. Pancreas. 2014. PMID: 24632546 Clinical Trial.

8

Safety and efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors.

Jiang Y, Liu Q, Wang G, Sui H, Wang R, Wang J, Zhang J, Zhu Z, Chen X. Jiang Y, et al. Theranostics. 2022 Sep 6;12(15):6437-6445. doi: 10.7150/thno.77219. eCollection 2022. Theranostics. 2022. PMID: 36185603 Free PMC article.

9

Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.

Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Thapa P, et al. Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547. Nucl Med Commun. 2016. PMID: 27243215

10

Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors.

Lee D, Li M, Liu D, Baumhover NJ, Sagastume EA, Marks BM, Rastogi P, Pigge FC, Menda Y, Johnson FL, Schultz MK. Lee D, et al. Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):1147-1162. doi: 10.1007/s00259-023-06494-9. Epub 2023 Nov 13. Eur J Nucl Med Mol Imaging. 2024. PMID: 37955792 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 34992153

179 results

Results by year